Citations

Clear

2429 citation(s) found for "Shah, SS".

Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer
Painter, Jodie N. , O’Mara, Tracy A. , Marquart, Louise , Webb, Penelope M. , Medland, Sarah E. , Cheng, Timothy, Holliday, Elizabeth , McEvoy, Mark , Scott, Rodney J. , Healey, Catherine S., Shah, Mitul , Gorman, Maggie, Martin, Lynn , Hodgson, Shirley V. , Beckmann, Matthias W. , Ekici, Arif B. , Fasching, Peter A. , Hein, Alexander , Rübner, Matthias, Darabi, Hatef, Li, Jingmei , Dörk, Thilo , Hillemanns, Peter , Runnebaum, Ingo B. , Annibali, Daniela , Depreeuw, Jeroen, Lambrechts, Diether , Neven, Patrick , Cunningham, Julie M. , Dowdy, Sean C. , Goode, Ellen L. , Winham, Stacey J. , Njølstad, Tormund S. , Salvesen, Helga B., Trovik, Jone , Werner, Henrica M.J., Ashton, Katie A. , Otton, Geoffrey, Proietto, Anthony , Mints, Miriam, Tham, Emma , Bolla, Manjeet K. , Michailidou, Kyriaki , Wang, Qin , Hopper, John L. , Peto, Julian , Swerdlow, Anthony J. , Burwinkel, Barbara , Brenner, Hermann , Meindl, Alfons, Brauch, Hiltrud , Lindblom, Annika , Chang‐Claude, Jenny , Couch, Fergus J. , Kristensen, Vessela N. , Tomlinson, Ian M., Dunning, Alison M. , Easton, Douglas F. , Thompson, Deborah J. , Lambrechts, Diether , Attia, John , Dennis, Joe , Ahmed, Shahana , Czene, Kamila , Hall, Per N , Dürst, Matthias , Amant, Frédéric , Fridley, Brooke L. , Mints, Miriam , Tyrer, Jonathan P. , Meindl, Alfons, Couch, Fergus J. , Giles, Graham G. , Cox, Angela , Pharoah, Paul D.P. , Spurdle, Amanda B. , Winham, Stacey J , Dörk, Thilo , Lambrechts, Diether , Webb, Penelope M , Hein, Alexander , Hillemanns, Peter , Swerdlow, Anthony J , Medland, Sarah E , O'Mara, Tracy A , Dunning, Alison M , Lambrechts, Diether , Brenner, Hermann , Li, Jingmei , Ekici, Arif B , Michailidou, Kyriaki , Brauch, Hiltrud , Lindblom, Annika

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | August 22, 2016 | Volume: 25 | Issue: 11 | Pages: 1503-1510

10.1158/1055-9965.epi-16-0147 | PMID 27550749 Get It

Abstract Background: The strongest known risk factor for endometrial cancer is obesity. To determine whether SNPs associated with increased body mass index (BMI) or waist–hip ratio (WHR) are associated with endometrial cancer risk, independent of measured BMI, we investigated relationships between 77 BMI and 47 WHR SNPs and endometrial cancer in 6,609 cases and 37,926 country-matched controls. Methods: Logistic regression analysis and fixed effects meta-analysis were used to test for associations between endometrial cancer risk and (i) individual BMI or WHR SNPs, (ii) a combined weighted genetic risk score (wGRS) for BMI or WHR. Causality of BMI for endometrial cancer was assessed using Mendelian randomization, with BMIwGRS as instrumental variable. Results: The BMIwGRS was significantly associated with endometrial cancer risk (P = 3.4 × 10−17). Scaling the effect of the BMIwGRS on endometrial cancer risk by its effect on BMI, the endometrial cancer OR per 5 kg/m2 of genetically predicted BMI was 2.06 [95% confidence interval (CI), 1.89–2.21], larger than the observed effect of BMI on endometrial cancer risk (OR = 1.55; 95% CI, 1.44–1.68, per 5 kg/m2). The association attenuated but remained significant after adjusting for BMI (OR = 1.22; 95% CI, 1.10–1.39; P = 5.3 × 10−4). There was evidence of directional pleiotropy (P = 1.5 × 10−4). BMI SNP rs2075650 was associated with endometrial cancer at study-wide significance (P < 4.0 × 10−4), independent of BMI. Endometrial cancer was not significantly associated with individual WHR SNPs or the WHRwGRS. Conclusions: BMI, but not WHR, is causally associated with endometrial cancer risk, with evidence that some BMI-associated SNPs alter endometrial cancer risk via mechanisms other than measurable BMI. Impact: The causal association between BMI SNPs and endometrial cancer has possible implications for endometrial cancer risk modeling. Cancer Epidemiol Biomarkers Prev; 25(11); 1503–10. ©2016 AACR.
Novel combination of ITGB2 mutations causing leukocyte adhesion deficiency type 1 (LAD-1)
Shah, Kunal , Pratt, Ellen, Al‐Rahawan, Mohamad M. , Abraham, Roshini S.

Mayo Clinic

Journal of Pediatric Infectious Diseases | August 17, 2016 | Volume: 06 | Issue: 02 | Pages: 141-148

10.3233/jpi-2011-0312 Get It

Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction
Redfield, Margaret M. , Givertz, Michael M. , Oliveira, Guilherme H., Cole, Robert T. , Whellan, David J. , Felker, G. Michael , McNulty, Steven E., Anstrom, Kevin J. , Cappola, Thomas P. , Margulies, Kenneth B. , Hernandez, Adrian F. , Mann, Douglas L. , Kiernan, Michael S. , Shah, Monica , Braunwald, Eugene

Mayo Clinic

JAMA | August 2, 2016 | Volume: 316 | Issue: 5 | Pages: 500

10.1001/jama.2016.10260 | PMID 27483064 Get It

Transcatheter valve implantation for right atrium‐to‐right ventricle conduit obstruction or regurgitation after modified Björk–fontan procedure
Horlick, Eric , Eicken, Andreas , Asnes, Jeremy D. , Bocks, Martin L. , Boudjemline, Younès , Fagan, Thomas E. , Schubert, Stephan , Mahadevan, Vaikom S. , Dvir, Danny , Osten, Mark , McElhinney, Doff B. , Cabalka, Allison K. , Shah, Ashish H. , McElhinney, Doff B

Mayo Clinic

Catheterization and Cardiovascular Interventions | July 28, 2016 | Volume: 89 | Issue: 2 | Pages: 298-305

10.1002/ccd.26648 | PMID 27465501 Get It

BackgroundThe most common reason for reintervention after a Björk modification of the Fontan procedure, in which the right ventricle (RV) is incorporated into the pulmonary circulation by connecting the right atrial (RA) appendage to the RV directly or with an extra‐anatomic graft, is obstruction or regurgitation of the RA–RV connection. Transcatheter implantation of a valved stent is an appealing option for the treatment of RA–RV conduit dysfunction in these patients. In the present study, we assessed early and intermediate results after transcatheter valve implantation within an obstructed or regurgitant RA–RV modified Fontan pathway.MethodsThrough a retrospective multicenter registry, we collected data from 16 patients with a modified Fontan circulation who were treated with percutaneous Melody or Sapien valve implantation for dysfunction of an extra‐anatomic RA–RV conduit or valve.ResultsAll patients had successful and uncomplicated implantation of a Melody (n = 15) or Sapien 3 (n = 1) valve with hemodynamic and, in most cases, clinical improvement. During a median follow‐up of 3.3 years, 3 patients died of cardiovascular causes unrelated to the procedure or the valve, and no major valve dysfunction was observed.ConclusionPercutaneous transcatheter valve deployment to treat a dysfunctional RA–RV connection after a Björk modification of the Fontan procedure is a viable alternative to surgery, with low procedural risk, and appears to offer good early and intermediate results.© 2016 Wiley Periodicals, Inc.
Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology an
Wiktor, Anne E., Meyer, Reid G., Tenner, Kathleen , Sukov, William R. , Ketterling, Rhett P. , Perez, Edith A. , Jenkins, Robert B. , Tenner, Kathleen S, Green, Stefan J. , Shah, Meera , Ballman, Karla V. , Ketterling, Rhett P

Mayo Clinic

Journal of Clinical Oncology | July 26, 2016 | Volume: 34 | Issue: 29 | Pages: 3502-3510

10.1200/jco.2015.61.8983 | PMID 27458302 Get It

Purpose In 1998, the US Food and Drug Administration (FDA) approved human epidermal growth factor receptor 2 (HER2) testing guidelines to determine eligibility for HER2-directed therapy (HDT) in breast cancer. ASCO and the College of American Pathologists published immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) HER2 testing guidelines in 2007 (AC2007) and updated these guidelines in 2013 (AC2013). We compared the HER2 FISH amplification frequency using these three guidelines. Methods Patient samples that were sent to the Mayo Clinic cytogenetics laboratory for FISH testing (n = 2,851; from November 2013 to October 2014) were analyzed. Frequency of HER2 FISH amplification was examined and impact of AC2013 assessed. Results IHC results were available for 1,922 patient samples (67.4%), 137 of which were from Mayo Clinic. Distribution was 2.4% IHC 0, 7.9% IHC 1+, 84.8% IHC 2+, and 2.5% IHC 3+. Among IHC 2+ patients, HER2 FISH positivity was 11.8% (FDA), 9.4% (AC2007), and 24.1% (AC2013). Overall, 11.8% (n = 339) were positive with a FISH ratio ≥ 2.0, 1.3% (n = 35) with a FISH ratio ≥ 2.0 despite a HER2 signal < 4.0, and 3.0% (n = 86) with HER2 signal ≥ 6.0 despite FISH ratio < 2.0. Among 405 patients (14.2%) who were initially considered FISH-equivocal (ratio < 2.0 with HER2 signal ≥ 4.0, but < 6.0; AC2013), use of an alternative chromosome 17 probe reassigned 212 (7.4% overall) patients to FISH-positive and 36 (1.3% overall) patients to FISH-negative, whereas 157 (5.5% overall) patients remained equivocal. Final HER2 positivity with AC2013 (23.6%) was increased (P < .001) compared with FDA (13.1%) and AC2007 (11%) guidelines. Conclusion In a reference laboratory cohort that was highly enriched for IHC 2+ patient samples, AC2013 guidelines led to a larger number of FISH-equivocal patients. Approximately one half of these FISH-equivocal patients (7.4% overall) became HER2-positive upon alternative FISH probe testing. However, these patients would not have participated in the pivotal HDT trials. Clinical utility data on HDT benefit in these patients and other special subsets are needed.
Investigating the KNDy Hypothesis in Humans by Coadministration of Kisspeptin, Neurokinin B, and Naltrexone in Men
Narayanaswamy, Shakunthala, Prague, Julia , Papadopoulou, Deborah , Mizamtsidi, Maria, Shah, Amar, Bassett, Paul , Comninos, Alexander , Abbara, Ali , Veldhuis, Johannes D. , Dhillo, Waljit S. , Prague, Julia K, Jayasena, Channa N, Papadopoulou, Deborah A, Shah, Amar J, Comninos, Alexander N, Bloom, Stephen R. , Jayasena, Channa

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 5, 2016 | Volume: 101 | Issue: 9 | Pages: 3429-3436

10.1210/jc.2016-1911 | PMID 27379743 Get It

AbstractContext:A subpopulation of hypothalamic neurons colocalize three neuropeptides, namely kisspeptin, neurokinin B (NKB), and dynorphin, collectively termed KNDy neurons. Animal studies suggest they interact to affect pulsatile GnRH release (KNDy hypothesis); kisspeptin stimulates, NKB modulates, and dynorphin (an opioid) inhibits.Objective:To investigate the KNDy hypothesis in humans, we assessed for the first time the effects of the coadministration of kisspeptin-54, NKB, and an opioid receptor antagonist, naltrexone, on LH pulsatility (surrogate marker for GnRH pulsatility) and gonadotropin release.Design, Setting, and Participants:This was an ethically approved prospective, single-blinded, placebo-controlled study. Healthy male volunteers (n = 5/group) attended our research facility for eight study visits.Intervention and Main Outcome Measure:After 1 hour of baseline blood sampling, participants received a different intervention at each visit: oral 50 mg naltrexone, 8-hour iv infusions of vehicle, 2.56 nmol/kg · h NKB, 0.1 nmol/kg · h kissspeptin-54 (KP) alone and in combination. Frequent blood sampling to measure plasma gonadotropins and sex steroids was conducted and LH pulsatility was determined using blinded deconvolution analysis.Results:All kisspeptin and naltrexone containing groups potently increased LH and LH pulsatility (P &lt; .001 vs vehicle). NKB alone did not affect gonadotropins. NKB+KP had significantly lower increases in gonadotropins compared with kisspeptin alone (P &lt; .01). Naltrexone+KP was the only group to significantly increase LH pulse amplitude (P &lt; .001 vs vehicle).Conclusions:Our results suggest significant interactions between the KNDy neuropeptides on LH pulsatility and gonadotropin release in humans. This has important implications for improving our understanding of GnRH pulse generation in humans.
Endothelial notch signaling is essential to prevent hepatic vascular malformations in mice
Cuervo, Henar , Nielsen, Corinne M. , Simonetto, Douglas A. , Ferrell, Linda D., Shah, Vijay H. , Wang, Rong A. , Simonetto, Douglas A

Mayo Clinic

Hepatology | June 30, 2016 | Volume: 64 | Issue: 4 | Pages: 1302-1316

10.1002/hep.28713 | PMID 27362333 Get It

Liver vasculature is crucial for adequate hepatic functions. Global deletion of Notch signaling in mice results in liver vascular pathologies. However, whether Notch in endothelium is essential for hepatic vascular structure and function remains unknown. To uncover the function of endothelial Notch in the liver, we deleted Rbpj, a transcription factor mediating all canonical Notch signaling, or Notch1 from the endothelium of postnatal mice. We investigated the hepatic vascular defects in these mutants. The liver was severely affected within 2 weeks of endothelial deletion of Rbpj from birth. Two‐week old mutant mice had enlarged vessels on the liver surface, abnormal vascular architecture, and dilated sinusoids. Vascular casting and fluorosphere passage experiments indicated the presence of porto‐systemic shunts. These mutant mice presented with severely necrotic liver parenchyma and significantly larger hypoxic areas, likely resulting from vascular shunts. We also found elevated levels of VEGF receptor 3 together with reduced levels of ephrin‐B2, suggesting a possible contribution of these factors to the generation of hepatic vascular abnormalities. Deletion of Rbpj from the adult endothelium also led to dilated sinusoids, vascular shunts, and necrosis, albeit milder than that observed in mice with deletion from birth. Similar to deletion of Rbpj, loss of endothelial Notch1 from birth led to similar hepatic vascular malformations within 2 weeks. Conclusions: Endothelial Notch signaling is essential for the development and maintenance of proper hepatic vascular architecture and function. These findings may elucidate the molecular pathogenesis of hepatic vascular malformation and the safety of therapeutics inhibiting Notch. (Hepatology 2016;64:1302‐1316)
Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction
Shah, Sanjiv J. , Kitzman, Dalane W. , Borlaug, Barry A. , Heerebeek, Loek van , Zile, Michael R. , Paulus, Walter J. , van Heerebeek, Loek, Kass, David A. , Shah, Sanjiv J , Borlaug, Barry A , Zile, Michael R

Mayo Clinic

Circulation | June 29, 2016 | Volume: 134 | Issue: 1 | Pages: 73-90

10.1161/circulationaha.116.021884 | PMID 27358439 Get It

Heart failure (HF) with preserved ejection fraction (EF; HFpEF) accounts for 50% of HF cases, and its prevalence relative to HF with reduced EF continues to rise. In contrast to HF with reduced EF, large trials testing neurohumoral inhibition in HFpEF failed to reach a positive outcome. This failure was recently attributed to distinct systemic and myocardial signaling in HFpEF and to diversity of HFpEF phenotypes. In this review, an HFpEF treatment strategy is proposed that addresses HFpEF-specific signaling and phenotypic diversity. In HFpEF, extracardiac comorbidities such as metabolic risk, arterial hypertension, and renal insufficiency drive left ventricular remodeling and dysfunction through systemic inflammation and coronary microvascular endothelial dysfunction. The latter affects left ventricular diastolic dysfunction through macrophage infiltration, resulting in interstitial fibrosis, and through altered paracrine signaling to cardiomyocytes, which become hypertrophied and stiff because of low nitric oxide and cyclic guanosine monophosphate. Systemic inflammation also affects other organs such as lungs, skeletal muscle, and kidneys, leading, respectively, to pulmonary hypertension, muscle weakness, and sodium retention. Individual steps of these signaling cascades can be targeted by specific interventions: metabolic risk by caloric restriction, systemic inflammation by statins, pulmonary hypertension by phosphodiesterase 5 inhibitors, muscle weakness by exercise training, sodium retention by diuretics and monitoring devices, myocardial nitric oxide bioavailability by inorganic nitrate-nitrite, myocardial cyclic guanosine monophosphate content by neprilysin or phosphodiesterase 9 inhibition, and myocardial fibrosis by spironolactone. Because of phenotypic diversity in HFpEF, personalized therapeutic strategies are proposed, which are configured in a matrix with HFpEF presentations in the abscissa and HFpEF predispositions in the ordinate.
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
Yao, Xiaoxi , Abraham, Neena S. , Sangaralingham, Lindsey R. , Bellolio, Fernanda , McBane, Robert D. , Shah, Nilay D. , Bellolio, M Fernanda, Noseworthy, Peter A. , McBane, Robert , Bellolio, M Fernanda , Yao, Xiaoxi

Mayo Clinic

Journal of the American Heart Association | June 14, 2016 | Volume: 5 | Issue: 6 | Pages: No page available

10.1161/jaha.116.003725 | PMID 27412905 Get It

Background The introduction of non–vitamin K antagonist oral anticoagulants has been a major advance for stroke prevention in atrial fibrillation; however, outcomes achieved in clinical trials may not translate to routine practice. We aimed to evaluate the effectiveness and safety of dabigatran, rivaroxaban, and apixaban by comparing each agent with warfarin. Methods and Results Using a large US insurance database, we identified privately insured and Medicare Advantage patients with nonvalvular atrial fibrillation who were users of apixaban, dabigatran, rivaroxaban, or warfarin between October 1, 2010, and June 30, 2015. We created 3 matched cohorts using 1:1 propensity score matching: apixaban versus warfarin (n=15 390), dabigatran versus warfarin (n=28 614), and rivaroxaban versus warfarin (n=32 350). Using Cox proportional hazards regression, we found that for stroke or systemic embolism, apixaban was associated with lower risk (hazard ratio [ HR ] 0.67, 95% CI 0.46–0.98, P =0.04), but dabigatran and rivaroxaban were associated with a similar risk (dabigatran: HR 0.98, 95% CI 0.76–1.26, P =0.98; rivaroxaban: HR 0.93, 95% CI 0.72–1.19, P =0.56). For major bleeding, apixaban and dabigatran were associated with lower risk (apixaban: HR 0.45, 95% CI 0.34–0.59, P <0.001; dabigatran: HR 0.79, 95% CI 0.67–0.94, P <0.01), and rivaroxaban was associated with a similar risk ( HR 1.04, 95% CI 0.90–1.20], P =0.60). All non–vitamin K antagonist oral anticoagulants were associated with a lower risk of intracranial bleeding. Conclusions In patients with nonvalvular atrial fibrillation, apixaban was associated with lower risks of both stroke and major bleeding, dabigatran was associated with similar risk of stroke but lower risk of major bleeding, and rivaroxaban was associated with similar risks of both stroke and major bleeding in comparison to warfarin.
Angiocrine signaling in the hepatic sinusoids in health and disease
Kostallari, Enis , Shah, Vijay H. , Kostallari, Enis

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | June 11, 2016 | Volume: 311 | Issue: 2 | Pages: G246-G251

10.1152/ajpgi.00118.2016 | PMID 27288423 Get It

The capillary network irrigating the liver is important not only for nutrient and oxygen delivery, but also for the signals distributed to other hepatic cell types necessary to maintain liver homeostasis. During development, endothelial cells are a key component in liver zonation. In adulthood, they maintain hepatic stellate cells and hepatocytes in quiescence. Their importance in pathobiology is highlighted in liver regeneration and chronic liver diseases, where they coordinate paracrine cell behavior. During regeneration, liver sinusoidal endothelial cells induce hepatocyte proliferation and angiogenesis. During fibrogenesis, they undergo morphological and functional changes, which are reflected by their role in hepatic stellate cell activation, inflammation, and distorted sinusoidal structure. Therapeutic strategies to target angiocrine signaling are in progress but are in the early stages. Here, we offer a short synthesis of recent studies on angiocrine signaling in liver homeostasis, regeneration, and fibrogenesis.